Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 725

1.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
[PubMed - indexed for MEDLINE]
2.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
[PubMed - indexed for MEDLINE]
3.

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN.

Drug Alcohol Depend. 1998 Mar 1;50(1):1-8.

PMID:
9589267
[PubMed - indexed for MEDLINE]
4.

Buprenorphine and naloxone interactions in opiate-dependent volunteers.

Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ.

Clin Pharmacol Ther. 1996 Jul;60(1):105-14.

PMID:
8689806
[PubMed - indexed for MEDLINE]
5.

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.

Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J.

Drug Alcohol Depend. 2000 Dec 22;61(1):85-94.

PMID:
11064186
[PubMed - indexed for MEDLINE]
6.

Buprenorphine and naloxone interactions in methadone maintenance patients.

Mendelson J, Jones RT, Welm S, Brown J, Batki SL.

Biol Psychiatry. 1997 Jun 1;41(11):1095-101.

PMID:
9146820
[PubMed - indexed for MEDLINE]
7.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.

PMID:
12738348
[PubMed - indexed for MEDLINE]
8.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
[PubMed - indexed for MEDLINE]
9.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
[PubMed - indexed for MEDLINE]
10.

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.

Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.

PMID:
17013637
[PubMed - indexed for MEDLINE]
11.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
[PubMed - indexed for MEDLINE]
12.

Modest opioid withdrawal suppression efficacy of oral tramadol in humans.

Lofwall MR, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2007 Oct;194(3):381-93. Epub 2007 Jul 1.

PMID:
17605004
[PubMed - indexed for MEDLINE]
13.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
[PubMed - indexed for MEDLINE]
14.

Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Amato P.

Clin Drug Investig. 2010;30 Suppl 1:33-9. doi: 10.2165/11536060-000000000-00000.

PMID:
20450244
[PubMed - indexed for MEDLINE]
15.

Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Rosado J, Walsh SL, Bigelow GE, Strain EC.

Drug Alcohol Depend. 2007 Oct 8;90(2-3):261-9. Epub 2007 May 22.

PMID:
17517480
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.

Wesson DR.

J Psychoactive Drugs. 2004 May;Suppl 2:119-28. Review.

PMID:
15279124
[PubMed - indexed for MEDLINE]
17.

Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):232-5.

PMID:
18087797
[PubMed - indexed for MEDLINE]
18.

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Alho H, Sinclair D, Vuori E, Holopainen A.

Drug Alcohol Depend. 2007 Apr 17;88(1):75-8. Epub 2006 Oct 19.

PMID:
17055191
[PubMed - indexed for MEDLINE]
19.

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD.

Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.

PMID:
20403021
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.

Strain EC, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2002 Jan;159(2):161-6. Epub 2001 Oct 12.

PMID:
11862344
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk